Compare Quest Diagnostics Inc (DGX) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while First Trust NASDAQ 100 Technology Index Fund trades at $331.55 (market cap $4.10B). The key difference: Quest Diagnostics Inc is far larger — about 6.2× First Trust NASDAQ 100 Technology Index Fund's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| DGX | QTEC | |
|---|---|---|
Market Cap | $25.48B | $4.10B |
Volume | 941,866 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $340.28 |
52-Week Low | $173.49 | $207.03 |
Typical Hold Time | 56 Days | 40 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
QTEC trades at $331.55, down 1.27% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, though key valuation and profitability ratios are unavailable in the provided data. Recent analysis highlights the software sector's undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar tech ETFs.
The outlook remains cautiously optimistic given the ETF's broad tech exposure and bullish technical trend, but risks include sector volatility and macroeconomic pressures. Investors should weigh the ETF's diversification benefits against potential headwinds in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
